Genetics and biology of prostate cancer

G Wang, D Zhao, DJ Spring… - Genes & …, 2018 - genesdev.cshlp.org
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types

V Constâncio, SP Nunes, R Henrique, C Jerónimo - Cells, 2020 - mdpi.com
Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal
population-based cancer screening methods remain an unmet need, since cancer detection …

Type I interferons in the pathogenesis and treatment of autoimmune diseases

J Jiang, M Zhao, C Chang, H Wu, Q Lu - Clinical reviews in allergy & …, 2020 - Springer
Abstract Type I interferons (IFN-Is) are a very important group of cytokines that are produced
by innate immune cells but also act on adaptive immune cells. IFN-Is possess antiviral …

Wnt/β-catenin signalling in prostate cancer

RM Kypta, J Waxman - Nature Reviews Urology, 2012 - nature.com
The Wnts are secreted cysteine-rich glycoproteins that have important roles in the
developing embryo as well as in tissue homeostasis in adults. Dysregulation of Wnt …

The mutational landscape of prostate cancer

CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig… - European urology, 2013 - Elsevier
Abstract Context Prostate cancer (PCa) is a clinically heterogeneous disease with marked
variability in patient outcomes. Molecular characterization has revealed striking mutational …

Aberrant PSA glycosylation—a sweet predictor of prostate cancer

S Gilgunn, PJ Conroy, R Saldova, PM Rudd… - Nature Reviews …, 2013 - nature.com
Prostate cancer—the most commonly diagnosed cancer in men worldwide—can have a
substantial effect on quality of life, regardless of the route the cancer takes. The serum PSA …

Genomic predictors of outcome in prostate cancer

PJ Boström, AS Bjartell, JWF Catto, SE Eggener… - European urology, 2015 - Elsevier
Context Given the highly variable behavior and clinical course of prostate cancer (PCa) and
the multiple available treatment options, a personalized approach to oncologic risk …

Mining cancer methylomes: prospects and challenges

C Stirzaker, PC Taberlay, AL Statham, SJ Clark - Trends in Genetics, 2014 - cell.com
There are over 28 million CpG sites in the human genome. Assessing the methylation status
of each of these sites will be required to understand fully the role of DNA methylation in …

Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy

M Montalvo-Casimiro, R González-Barrios… - Frontiers in …, 2020 - frontiersin.org
Gene mutations are strongly associated with tumor progression and are well known in
cancer development. However, recently discovered epigenetic alterations have shown the …

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth

X Deng, G Shao, HT Zhang, C Li, D Zhang, L Cheng… - Oncogene, 2017 - nature.com
Abstract Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme
that mainly represses transcription of target genes via symmetric dimethylation of arginine …